Inventor · disambiguated record
Xueming Qian
Also filed as: QIAN XUEMING
12 granted patents·14 pending applications·75 citations·filing 2001–2023
88Inventor score
Files withSUZHOU TRANSCENTA THERAPEUTICS CO LTD10AMGEN INC5JIANGSU HENGRUI MEDICINE CO3QIAN XUEMING2VARNUM BRIAN2
Top patents by PatentIndex Score
26 records- 0194US7438910B2Therapeutic human anti-IL1-R1 monoclonal antibodyAMGEN INC·Filed 2003·Granted Oct 21, 2008·54 cites·34 claims
- 0288US8043620B2Wise binding agents and epitopesAMGEN INC·Filed 2008·Granted Oct 25, 2011·13 cites·5 claims
- 0376US9534053B2Therapeutic human anti-IL-1R1 monoclonal antibodyMEDAREX LLC·Filed 2014·Granted Jan 3, 2017·2 cites·21 claims
- 0473US8518407B2Therapeutic human anti-IL-1R1 monoclonal antibodyVARNUM BRIAN·Filed 2012·Granted Aug 27, 2013·2 cites·26 claims
- 0572US8236559B2Therapeutic human anti-IL-1R1 monoclonal antibodyVARNUM BRIAN·Filed 2008·Granted Aug 7, 2012·1 cites·40 claims
- 0669US11525005B2Anti-CD40 antibody, antigen binding fragment thereof and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Dec 13, 2022·1 cites·25 claims
- 0767US8309092B2Wise binding agents and epitopesQIAN XUEMING·Filed 2011·Granted Nov 13, 2012·2 cites·5 claims
- 0860US8710203B2Therapeutic human anti-IL-1R1 monoclonal antibodyAMGEN INC·Filed 2013·Granted Apr 29, 2014·0 cites·24 claims
- 0959US2005084493A1Screening method for antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereofAMGEN INC·Filed 2004·Application pending·0 cites
- 1055US2024190950A1Method of treating diseases using gremlin1 antagonistsUNIV SHANGHAI JIAOTONG·Filed 2022·Application pending·0 cites
- 1155US2025282874A1Bifunctional protein, and preparation thereof and use thereofSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2023·Application pending·0 cites
- 1254US2025326834A1Combination therapy of claudin 18.2 antagonist and pd-1/pd-l1 axis inhibitorSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 1352US11753473B2Anti-PD-L1 antibodiesSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2020·Granted Sep 12, 2023·0 cites·28 claims
- 1452US2024309113A1Novel anti-masp-2 antibodiesSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 1550US2024043566A1Bi-functional moleculesSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2021·Application pending·0 cites
- 1650US2003026806A1Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereofAMGEN INC·Filed 2001·Application pending·0 cites
- 1750US2024307564A1Anti-cldn18.2 antibody conjugatesSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 1848US2024294622A1Novel anti-gremlin1 antibodiesSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 1948US2022025060A1Anti-cd40 antibody, antigen binding fragmentand pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 2047US12162944B2Human IL-4R binding antibody, antigen binding fragment thereof, and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Dec 10, 2024·0 cites·18 claims
- 2147US10822416B2Anti-PD-L1 antibodiesMABSPACE BIOSCIENCES SUZHOU CO LTD·Filed 2017·Granted Nov 3, 2020·0 cites·28 claims
- 2247US10233249B2Antibodies and methods for treating estrogen receptor-associated diseasesBEIJING SHENOGEN PHARMA GROUP LTD·Filed 2014·Granted Mar 19, 2019·0 cites·14 claims
- 2347US2023331836A1Anti-cldn18.2 antibodies and diagnostic uses thereofSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2021·Application pending·0 cites
- 2445US2024209099A1Novel anti-hvegfr2 antibodiesSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 2542US2022306765A1Novel anti-cldn18.2 antibodiesSUZHOU TRANSCENTA THERAPEUTICS CO LTD·Filed 2020·Application pending·0 cites
- 2628US2012288507A1Wise binding agents and epitopesQIAN XUEMING·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Xueming Qian files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →